The Role of APOE ε4 in Alzheimer's Disease: Brain Changes, Mechanism and Research Evidence

[1]Hanna Sunkara and [2]Vinutha U. Muktamath

[1]Ph.D, Department of Human Development and Family Studies, College of Community Science, University of Agricultural Sciences, Dharwad -580005, Karnataka, India.

[2]Assistant Professor & Scientist, Dept. of Human Development and Family Studies, College of Community Science, University of Agricultural Sciences, Dharwad, Karnataka, India.

Abstract

Alzheimer's disease (AD) is the most common cause of dementia worldwide and represents a growing public health concern. Among all genetic risk factors for late-onset Alzheimer's disease (LOAD), the strongest and most consistently identified is the APOE ε4 allele. Individuals carrying one or two copies of APOE ε4 have a significantly increased risk of developing Alzheimer's disease and often show earlier onset and faster progression. Research findings from genetic epidemiology, neuroimaging, and biomarker studies demonstrate that APOE ε4 promotes amyloid-β accumulation, accelerates tau pathology, increases neuroinflammation, and leads to faster brain atrophy. This article explains in detail how APOE ε4 affects the brain and summarizes key scientific findings supporting its central role in Alzheimer's disease.

Introduction

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. Pathologically, it is defined by:

- Extracellular amyloid-β (Aβ) plaques
- Intracellular neurofibrillary tangles composed of tau protein
- Synaptic loss and neuronal death
- Brain shrinkage (atrophy)

While aging is the strongest overall risk factor, genetics plays a major role in determining individual susceptibility. Among the many genes studied, APOE has emerged as the most influential genetic factor in late-onset Alzheimer's disease.

The APOE gene produces apolipoprotein E, a protein involved in:

- Cholesterol and lipid transport
- Neuronal repair
- Synaptic maintenance
- Immune regulation in the brain

There are three major alleles:

- **ε2** – Protective
- **ε3** – Neutral
- **ε4** – High-risk

Approximately 15–20% of the global population carries at least one APOE ε4 allele, but its frequency is much higher among individuals with Alzheimer's disease.

APOE ε4 Affects Alzheimer's Disease

1. Increased Amyloid-β Accumulation

One of the earliest events in Alzheimer's disease is the buildup of amyloid-β plaques.



https://ars.els-cdn.com/content/image/1-s2.0-S2211383521003944-ga1.jpg

Mechanism

APOE ε4:

- Reduces clearance of amyloid-β from the brain
- Promotes aggregation of Aβ into plaques
- Enhances deposition in cortical and hippocampal regions

Research Findings

- A landmark study by Corder et al. (1993) showed that Alzheimer's risk increases with the number of ε4 alleles (gene-dose effect).
- Amyloid PET imaging studies demonstrate that APOE ε4 carriers accumulate amyloid 10–15 years earlier than non-carriers.
- Population-based analyses reveal that individuals with two ε4 alleles may have up to 8–12 times higher risk of Alzheimer's disease.

These findings confirm that APOE ε4 accelerates the amyloid cascade central to AD pathology.

2. Enhanced Tau Pathology

Tau protein stabilizes neuronal microtubules. In Alzheimer's disease, tau becomes hyperphosphorylated and forms tangles.

Mechanism

APOE ε4:

- Amplifies tau-mediated neuronal toxicity
- Facilitates tau spread across connected brain regions
- Increases vulnerability of hippocampal neurons**Research Findings**
- Neuroimaging studies show higher tau PET signal in ε4 carriers with similar amyloid levels compared to non-carriers.
- Longitudinal cohort studies demonstrate that ε4 carriers experience faster tau accumulation and more rapid cognitive decline.

This suggests that APOE ε4 worsens disease progression beyond amyloid accumulation alone.

3. Accelerated Brain Atrophy

Brain shrinkage is a visible marker of neurodegeneration.

Mechanism

APOE ε4 contributes to:

- Hippocampal volume loss
- Cortical thinning
- Ventricular enlargement

Research Findings

- MRI studies consistently show faster hippocampal atrophy in ε4 carriers.
- Large biobank analyses report steeper age-related brain volume decline among individuals with high APOE-related genetic risk.
- Cognitive decline in memory and executive function correlates strongly with hippocampal shrinkage in ε4 carriers.

These findings confirm that APOE ε4 speeds structural brain degeneration.

4. Increased Neuroinflammation

Microglia are immune cells that protect the brain. In Alzheimer's disease, chronic inflammation becomes harmful.

Mechanism

APOE ε4:

- Overactivates microglia
- Increases pro-inflammatory cytokine release
- Reduces the brain's ability to regulate immune responses

Research Findings

- Molecular studies show higher inflammatory marker expression in ε4 carriers.
- Postmortem brain analyses reveal stronger microglial activation in individuals carrying APOE ε4.

Chronic inflammation amplifies amyloid and tau toxicity, accelerating neurodegeneration.

5. Impaired Lipid Transport and Synaptic Repair

The brain depends on cholesterol transport for membrane repair and synapse formation.

Mechanism

APOE ε4:

- Is less efficient at lipid transport
- Increases oxidative stress
- Reduces synaptic plasticity
- Weakens neuronal repair capacity

Research Findings

- Experimental studies demonstrate reduced dendritic spine density in APOE ε4 models.
- Cognitive testing shows earlier memory impairment in ε4 carriers even before dementia diagnosis.

This explains why ε4 carriers often show subtle cognitive changes earlier in life.

6. Dose-Dependent and Population-Level Effects

The impact of APOE ε4 depends on allele number:

- One ε4 allele → 2–3 times higher risk
- Two ε4 alleles → 8–12 times higher risk

Recent large-scale epidemiological studies involving hundreds of thousands of participants show:

- APOE ε4 accounts for a significant proportion of Alzheimer's cases globally.
- Population Attributable Fraction (PAF) analyses indicate that a substantial percentage of AD cases could theoretically be reduced if ε4-related risk pathways were modified.

Interaction Between APOE ε4 and Aging

Aging reduces:

- Amyloid clearance efficiency
- Mitochondrial function
- Neuronal repair mechanisms

When APOE ε4 is present:

- Amyloid accumulation accelerates
- Tau pathology intensifies
- Brain network connectivity declines faster

Longitudinal functional MRI studies reveal that ε4 carriers show earlier disruption in the Default Mode Network (DMN), a key memory-related brain network. Thus, aging and APOE ε4 act synergistically, significantly increasing disease vulnerability.

Conclusion

The APOE ε4 allele is the most powerful genetic risk factor for late-onset Alzheimer's disease. Extensive research evidence demonstrates that it:

- Promotes early amyloid-β accumulation
- Enhances tau pathology
- Accelerates hippocampal atrophy
- Increases chronic neuroinflammation
- Impairs synaptic repair and lipid metabolism
- Causes dose-dependent risk elevation

Importantly, APOE ε4 does not guarantee disease but increases susceptibility. Its interaction with aging determines the timing and severity of Alzheimer's progression. Understanding APOE ε4 biology has transformed Alzheimer's research and opened pathways for:

- Genetic risk assessment
- Early biomarker detection
- Targeted therapeutic strategies
- Precision medicine approaches

Future treatments may focus on modifying APOE-related pathways to slow or prevent neurodegeneration in high-risk individuals.

References

Corder, E. H., Saunders, A. M., Strittmatter, W. J., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease. *Science*, 261(5123), 921–923.

Liu, C. C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. *Nature Reviews Neurology*, 9(2), 106–118.

Jack, C. R., Bennett, D. A., Blennow, K., et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia*, 14(4), 535–562.

Reitz, C., & Mayeux, R. (2014). Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. *Biochemical Pharmacology*, 88(4), 640–651.

Strittmatter, W. J., & Roses, A. D. (1996). Apolipoprotein E and Alzheimer's disease. *Annual Review of Neuroscience*, 19, 53–77.

* * * * * * * * *